<DOC>
	<DOCNO>NCT01135329</DOCNO>
	<brief_summary>This research do learn reduced-intensity bone marrow transplantation ( BMT ) , also know `` mini '' transplant patient blood cancer , use bone marrow relative . The main goal study determine quickly donor 's bone marrow `` take '' body . Other goal include describe many people accept bone marrow quickly blood count come ; describe Graft-versus-host disease ( GVHD ) complication ; describe many people survive without progressive cancer survive overall</brief_summary>
	<brief_title>Reduced-intensity , Related-donor Bone Marrow Transplantation Followed High-dose Cyclophosphamide Hematologic Cancers</brief_title>
	<detailed_description>At present time cure people cancer blood lymph gland outside bone marrow transplant ( BMT ) . BMT develop several decade research effective treatment various malignant nonmalignant hematologic disease . This research do learn reduced-intensity bone marrow transplantation ( BMT ) , also know `` mini '' transplant patient blood cancer , use bone marrow relative . The bone marrow transplant come relative half-match `` haplo '' match . Possible donor include parent , sibling , child . `` Mini '' transplant give many people various cancer consider experimental . Over 200 people Johns Hopkins receive mini transplant high dos cyclophosphamide transplant . However , chemotherapy combination treatment give transplant different study . Although chemotherapy immune-lowering drug use study approve Food Drug Administration ( FDA ) , combination medication use study FDA approve experimental .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Firstdegree relate donor minimum HLA haploidentical Eligible diagnosis : 1 . Lowgrade nonHodgkin 's lymphoma plasma cell neoplasm progress multiagent therapy , fail least two prior therapy ( exclude single agent rituximab single agent steroid ) , case lymphoma undergone histological conversion : Follicular grade 1 2 lymphoma Follicular lymphoma otherwise specify Marginal zone ( MALT ) lymphoma Lymphoplasmacytic lymphoma / Waldenstrom 's macroglobulinemia Hairy cell leukemia Small lymphocytic lymphoma ( SLL ) chronic lymphocytic leukemia ( CLL ) Prolymphocytic leukemia Low grade Bcell lymphoma , unspecified Multiple myeloma Plasma cell leukemia 2 . Poorrisk SLL CLL , define 11q 17p deletion , histological conversion , disease progression &lt; 6 month purine analogcontaining regimen 3 . Aggressive lymphoma fail least one prior regimen multiagent chemotherapy , patient either ineligible autologous BMT autologous BMT recommend : Hodgkin lymphoma Follicular grade 3 lymphoma Mantle cell lymphoma leukemia Diffuse large Bcell lymphoma ( exclude primary CNS lymphoma ) . Eligible subtypes include primary mediastinal large Bcell lymphoma , Tcell rich large Bcell lymphoma , large Bcell lymphoma otherwise specify . Burkitt 's lymphoma/leukemia Atypical Burkitt 's lymphoma/leukemia ( high grade Bcell lymphoma , unclassified , include feature intermediate Burkitt 's diffuse large Bcell lymphoma ) Anaplastic large cell lymphoma Plasmablastic lymphoma Peripheral Tcell lymphoma 4 . Relapsed refractory acute leukemia second subsequent remission 5 . Poorrisk acute leukemia first remission 6 . AML least one following : AML arise MDS myeloproliferative disorder , secondary AML Presence Flt3 internal tandem duplication Poorrisk cytogenetics Primary refractory disease ALL ( leukemia and/or lymphoma ) least one following : Adverse cytogenetics Clear evidence hypodiploidy Primary refractory disease Biphenotypic leukemia MDS least one follow feature : Poorrisk cytogenetics IPSS score INT2 great Treatmentrelated MDS MDS diagnose age 21 year Progression lack response standard DNAmethyltransferase inhibitor therapy Lifethreatening cytopenia , include generally require great weekly transfusion 7 . Interferon imatinibrefractory CML first chronic phase , nonblast crisis CML beyond first chronic phase 8 . Philadelphia chromosome negative myeloproliferative disease ( include myelofibrosis ) 9 . Chronic myelomonocytic leukemia 10 . Juvenile myelomonocytic leukemia For patient SLL , CLL , prolymphocytic leukemia , &lt; 20 % bone marrow cellularity involve process Adequate endorgan function : Left ventricular ejection fraction great equal 35 % Bilirubin â‰¤ 3.0 mg/dL ( unless due Gilbert 's syndrome hemolysis ) , ALT AST &lt; 5 x ULN FEV1 FVC &gt; 40 % predict ; pediatric patient , unable perform pulmonary function test due young age , oxygen saturation &gt; 92 % room air ECOG performance status &lt; 2 Karnofsky Lansky score &gt; 60 Pregnant breastfeeding Uncontrolled infection Note : Infection permit evidence response medication . Eligibility HIV infect patient determined casebycase basis . Any previous BMT within 3 month prior start condition Active extramedullary leukemia know active Central Nervous System ( CNS ) involvement malignancy . Such disease treat remission permit .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Hodgkin 's lymphoma</keyword>
	<keyword>Non hodgkin 's lymphoma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Acute myeloid leukemia ( AML )</keyword>
	<keyword>Acute lymphoblastic leukemia ( ALL )</keyword>
	<keyword>Chronic myeloid leukemia ( CML )</keyword>
	<keyword>Chronic Myelomonocytic ( CMML )</keyword>
	<keyword>Myelodysplastic syndrome ( MDS )</keyword>
	<keyword>High-risk acute leukemia first remission</keyword>
	<keyword>Relapsed leukemia remission</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>High-dose cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Allogeneic</keyword>
	<keyword>Nonmyeloablative</keyword>
	<keyword>Reduced intensity</keyword>
	<keyword>Haploidentical</keyword>
	<keyword>Bone marrow transplant ( BMT )</keyword>
</DOC>